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Abstract 
Genome-wide gene expression profile analyses revealed that Ras and EF-hand 
domain containing (RASEF) was significantly transactivated in the majority of 
lung cancers.  Transient expression of RASEF promoted cell growth, whereas 
transfection of siRNA for RASEF to lung cancer cells reduced its expression and 
resulted in growth suppression of the cancer cells.  Immunohistochemical 
staining using tumor tissue microarrays consisting of 341 archived non-small cell 
lung cancers revealed the association of strong RASEF positivity with poor 
prognosis (P = 0.0034 by multivariate analysis).  RASEF could bind to 
extracellular signal-regulated kinase (ERK) 1/2 and appeared to enhance the 
ERK1/2 signaling.  In addition, inhibition of interaction between RASEF and 
ERK1/2 using cell-permeable peptide that corresponded to the 
ERK1/2-interacting site of RASEF protein, suppressed growth of lung cancer 
cells.  RASEF may play important roles in lung carcinogenesis, and could be 
useful as a prognostic biomarker and a target for the development of new 
molecular therapies. 
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Introduction 
Lung cancer is the most common cause of cancer-related death in the world and 
its incidence has been increasing (1).  In spite of the use of advanced surgical 
treatments combined with radiotherapy and chemotherapy, the overall 5-year 
survival rate of lung cancer patients still remains at 20% (2).  Development of 
molecular targeted drugs such as gefitinib and bevacizumab have improved 
treatment modalities of lung cancer, but fatal adverse events such as interstitial 
pneumonia by gefitinib or severe hemorrhage by bevacizumab were reported 
(3–4).  Therefore, further development of new agents targeting cancer-specific 
molecules with no or minimum risk of adverse effect is urgently awaited.  To 
date, clinical and pathological staging have been the most reliable information 
for physicians in the choice of therapy.  However, considering that about 30% 
of stage I non-small-cell lung cancer (NSCLC) patients who had undergone 
curative surgery suffered recurrent diseases (2), it is important to develop more 
precise prognostic biomarkers for selecting patients who should be treated with 
adjuvant therapies and intensively followed after surgical treatment. 
Systematic analysis of expression levels of thousands of genes using a cDNA 
microarray technology is an effective approach for identifying molecules involved 
in pathways of carcinogenesis or those associated with efficacy/resistance to 
anticancer therapy; some of such genes or their gene products may be good 
target molecules for the development of novel therapies and/or cancer 
biomarkers (5).  To identify such molecules, particularly oncoantigens, we had 
performed genome-wide expression profile analysis of 120 clinical lung cancer 
tissue samples, coupled with enrichment of tumor cells by laser microdissection, 
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and then compared the expression profile data with those in 31 normal human 
tissues (27 adult and 4 fetal organs) (6–10).  To verify the clinicopathological 
significance of the respective gene products, we have established a screening 
system by a combination of the tumor-tissue microarray analysis of clinical lung 
cancer materials and RNA interference technique (11–41).  This systematic 
approach revealed that RAS and EF-hand domain containing (RASEF) is likely 
to be a novel molecule that was overexpressed commonly in primary lung 
cancers and was essential for cell growth and/or survival of cancer cells. 
RASEF contains a Rab GTPase domain in the C-terminal region and is 
considered as a member of Rab GTPase protein family.  Unlike other Rab 
proteins, RASEF contains two EF-hand domains which are generally known to 
be important for binding to calucium ions in the N-terminus and a coiled-coil motif 
in an internal region (42).  The functional relevance of RASEF activation to 
carcinogenesis as well as its detailed biological function has not yet been 
defined.  We here report the first evidence that RASEF plays a significant role 
in lung cancer cell growth possibly through its interaction with extracellular 
signal-regulated kinase (ERK) 1/2, and suggest that RASEF could be a 
promising prognostic biomarker and therapeutic target for lung cancer. 
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Materials and Methods 
Cell lines and tissue samples 
Lung cancer cell lines and human bronchial epithelial cells (BEAS-2B) used in 
this study were listed in Supplementary Table S1.  A427, A549, NCI-H1373, 
NCI-H1781, NCI-H358, NCI-H226, NCI-H520, NCI-H2170, NCI-H1703, DMS114, 
DMS273, NCI-H196 NCI-H446, and BEAS-2B cells were from American Type 
Culture Collection in 2003, 2010 and 2011, and tested and authenticated by DNA 
profiling for polymorphic short tandem repeat (STR) markers.  PC-3, SBC-3 and 
SBC-5 cells were from Japanese Collection of Research Bioresources (JCRB) in 
2001 and 2010, and tested and authenticated by DNA profiling for polymorphic 
short tandem repeat (STR) markers.  PC-14, EBC-1 and RERF-LC-AI cells 
were from RIKEN BioResource Center in 2001 and 2010, and tested and 
authenticated by DNA profiling for polymorphic short tandem repeat (STR) 
markers.  LC319 cells were from Aichi Cancer Center in 2003, and tested and 
authenticated by DNA profiling for single-nucleotide polymorphism, mutation, 
and deletion analysis.  PC-9 and LX1 cells were from Tokyo Medical University 
and Central Institute for Experimental Animals and European Collection of 
Animal Cell Cultures in 2002, and tested and authenticated by DNA profiling for 
single-nucleotide polymorphism, mutation, and deletion analysis.  All cells were 
grown in monolayer in appropriate medium supplemented with 10% FCS and 
maintained at 37°C in humidified air with 5% CO2.  Primary lung cancer 
samples had been obtained earlier as previously described (6, 10).  All tumors 
were staged on the basis of the pTNM pathological classification of the UICC 
(International Union Against Cancer) (43).  A total of 341 formalin-fixed samples 
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of primary NSCLCs (100 female and 241 male patients; median age of 65 with a 
range of 35-85 years; 93 never smoke cases and 248 ex- or current smokers; 
205 adenocarcinomas (ADCs), 105 suqamous cell carcinomas (SCCs), 11 
adenosquamous cell carcinoma (ASCs), 20 large cell carcinoma (LCCs); 141 
pT1, 157 pT2 and 43 pT3 cases; 223 pN0, 42 pN1, and 76 pN2 cases: see 
Supplementary Table S2) had been obtained earlier along with 
clinicopathological data from patients undergoing surgery at Saitama Cancer 
Center (Saitama, Japan).  Independent set of 243 formalin-fixed samples of 
primary NSCLCs for validation study was obtained by Hokkaido University and 
its affiliated hospitals (Sapporo, Japan).  These patients received resection of 
their primary cancers, and among them only patients with positive lymph node 
metastasis were treated with cisplatin-based adjuvant chemotherapies after their 
surgery.  This study and the use of all clinical materials mentioned were 
approved by individual institutional Ethical Committees. 
 
Semi-quantitative reverse transcription-PCR  
A total of 3 µg aliquot of mRNA from each sample was reversely transcribed to 
single-stranded cDNAs using random primer (Roche Diagnostics) and 
SuperScript II (Invitrogen).  Semi-quantitative reverse transcription-PCR 
(RT-PCR) experiments were carried out with the following sets of synthesized 
gene-specific primers or with β-actin (ACTB)-specific primers as an internal 
control: RASEF, 5’-GGCTGACATTCGTGACACTG-3’ and 
5’-GGAATTGGTCCCGGTTAGAT-3’; Cyclin D1 (CCND1), 
5’-CCTCGGTGTCCTACTTCAAA-3’ and 5’-CCAGGTTCCACTTGAGCTTGT-3’; 
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Cyclin B1 (CCNB1), 5’-TTGGTGTCACTGCCATGTTT-3’ and 
5’-GATGCTCTCCGAAGGAAGTG-3’; Cyclin-dependent kinase inhibitor 1A 
(CDKN1A), 5’-TTAGCAGCGGAACAAGGAGT-3’ and 
5’-ATTCAGCATTGTGGGAGGAG-3’; beta-actin (ACTB), 
5’-GAGGTGATAGCATTGCTTTCG-3’ and 
5’-CAAGTCAGTGTACAGGTAAGC-3’.  PCRs were optimized for the number 
of cycles to ensure product intensity to be within the linear phase of 
amplification. 
 
Western blot analysis 
Cell lysates from lung cancer cell line or normal airway epithelial cells were 
subjected to Western blotting.  In brief, cells were incubated in 1 mL lysis buffer 
(0.5% NP-40, 50mmol/L Tris-HCl, 150mmol NaCl) in the presense of protease 
inhibitor (Protease Inhibitor Cocktail Set III; Calbiochem).  Western blotting 
were done using an ECL Western-blotting analysis system (GE Healthcare 
Bio-sciences) as described previously (11-15).  A commercially available rabbit 
polyclonal antibody to human RASEF (Catalog No. 11569-1-AP, Proteintech 
Group, Inc.) was confirmed to be specific to endogenous RASEF protein by 
Western-blot analysis using lysates of lung cancer cell lines as well as normal 
airway epithelial cells (negative control). 
 
Immunocytochemical analysis  
Cells were plated onto glass coverslips (Becton Dickinson Labware), fixed with 
4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in PBS for 3 
on August 8, 2013. © 2013 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 16, 2013; DOI: 10.1158/1541-7786.MCR-12-0685-T 
8 
 
min at room temperature.  Nonspecific binding was blocked by Casblock 
(ZYMED) for 10 min at room temperature.  Cells were then incubated for 
overnight at 4°C with a rabbit polyclonal antibody to RASEF (Catalog No. 
11569-1-AP, Proteintech Group, Inc.) diluted in PBS containing 1% BSA.  After 
being washed with PBS, the cells were stained by Alexa 488-conjugated 
secondary antibody (Invitrogen) for 60 min at room temperature.  After another 
wash with PBS, each specimen was mounted with Vectashield (Vector 
Laboratories, Inc.) containing 4’,6-diamidino-2-phenylindole (DAPI) and 
visualized with Spectral Confocal Scanning Systems (TSC SP2 AOBS; Leica 
Microsystems). 
 
Northern blot analysis   
Human multiple tissue blots covering 16 tissues (BD Biosciences) were 
hybridized with an [α-32P]-dCTP-labeled, 421-bp PCR product of RASEF that 
was prepared as a probe using primers 5’-GGCTGACATTCGTGACACTG-3’ 
and 5’-CAAAGTTCCAGAGGGACCTG-3’.  Prehybridization, hybridization, and 
washing were done following the manufacturer’s specifications.  The blots were 
autoradiographed with intensifying screens at -80°C for 10 days. 
 
Immunohistochemistry and tissue microarray 
To investigate the clinicopathological significance of RASEF overexpression in 
lung cancers, we stained tissue sections using ENVISION+ Kit/HRP 
(DakoCytomation).  Anti-RASEF rabbit polyclonal antibody (Catalog No. 
11569-1-AP, Proteintech Group, Inc.) was added after blocking of endogenous 
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peroxidase and proteins, and each section was incubated with HRP-labeled 
anti-rabbit IgG as the secondary antibody.  Substrate-chromogen was added 
and the specimens were counterstained with hematoxylin. 
Tumor tissue microarrays were constructed with formalin-fixed 341 primary lung 
cancers, each of which had been obtained with an identical protocol to collect, fix, 
and preserve the tissues after resection (12-18).  The tissue area for sampling 
was selected based on visual alignment with the corresponding H&E-stained 
section on a slide.  Three, four, or five tissue cores (diameter, 0.6 mm; depth, 
3–4 mm) taken from a donor tumor block were placed into a recipient paraffin 
block with a tissue microarrayer (Beecher Instruments).  A core of normal tissue 
was punched from each case, and 5-µm sections of the resulting microarray 
block were used for immunohistochemical analysis.  Three independent 
investigators semi-quantitatively assessed RASEF positivity without prior 
knowledge of clinicopathologic information.  The intensity of RASEF staining 
was evaluated using the following criteria: strong positive (scored as 2+), brown 
staining in > 50% of tumor cells completely obscuring cytoplasm; weak positive 
(1+), any lesser degree of brown staining appreciable in tumor cell cytoplasm; 
and absent (scored as 0), no appreciable staining in tumor cells.  Cases were 
accepted as strongly positive only if two or more investigators independently 
defined them as such. 
 
Statistical analysis 
Statistical analyses were done using the StatView statistical program (SAS).  
Tumor-specific survival curves were calculated from the date of surgery to the 
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time of death related to NSCLC or to the last follow-up observation.  
Kaplan-Meier curves were calculated for each relevant variable and for RASEF 
expression; differences in survival times among patient subgroups were 
analyzed using the log-rank test.  Univariate and multivariate analyses were 
done with the Cox proportional hazard regression model to determine 
associations between clinicopathological variables and cancer-related mortality.  
First, we analyzed associations between death and possible prognostic factors, 
including age, gender, smoking status, pathologic tumor classification, and 
pathologic node classification, taking into consideration one factor at a time.  
Second, multivariate Cox analysis was applied on backward (stepwise) 
procedures that always forced strong RASEF expression into the model, along 
with any and all variables that satisfied an entry level of a P value of < 0.05.  As 
the model continued to add factors, independent factors did not exceed an exit 
level of P < 0.05. 
 
RNA interference assay 
To evaluate the biological functions of RASEF in lung cancer cells, we used 
small interfering RNA (siRNA) duplexes against RASEF.  The target sequences 
of the synthetic oligonucleotides for RNA interference were as follows: control 1 
(EGFP: enhanced green fluorescent protein (GFP) gene, a mutant of Aequorea 
victoria GFP), 5’-GAAGCAGCACGACUUCUUC-3’; control 2 (LUC: luciferase 
gene from Photinus pyralis), 5’-CGTACGCGGAATACTTCGA-3’; 
siRNA-RASEF-#1, 5’-GTTAGTACCTTGTACCAAA-3’; siRNA-RASEF-#2, 
5’-CTTCATCCGTGAGATCAGA-3’.  siRNAs were transfected into lung cancer 
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cell lines, A549 and NCI-H2170 using 30 μL of Lipofectamine 2000 (Invitrogen) 
following the manufacturer's protocol.  Cell numbers and viability were 
measured by Giemsa staining and triplicate MTT assays (cell counting kit-8 
solution; Dojindo Laboratories) at 5 days after the transfection.  Expression of 
endogenous RASEF protein was detected by Western blotting. 
 
Cell growth assays   
Endogenous RASEF-negative BEAS-2B and DMS114 cells transfected either 
with RASEF expression vector (pCAGGSn3FH-RASEF), which express RASEF 
with 3 X Flag sequences (DYKDHDGDYKDHDIDYKDDDDK) at the 
NH2-terminal or with mock vector (pCAGGSn3FH) were seeded onto six-well 
plates (5 X 104 cells/well), and maintained in medium containing 10% FBS and 
geneticin.  After 120 hours, cell proliferation was evaluated by the MTT assay 
using Cell Counting Kits (Dojindo Laboratories). 
 
Immunoprecipitation assay   
To examine the interaction between endogenous RASEF and ERK1/2, 
immunoprecipitation was performed with a rabbit polyclonal anti-RASEF 
antibody (Catalog No. 11569-1-AP, Proteintech Group, Inc.) at 4°C for 2 hours 
after incubation of extracts from NCI-H2170 cells at 4°C for 1 hour with protein 
G-Agarose beads as described previously (14).  The immunoprecipitates were 
washed five times with lysis buffer, and were subjected to Western blotting with a 
mouse monoclonal anti-ERK1/2 antibody (Catalog. No. 4696; Cell Signaling 
Technology). 
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Identification of ERK1/2-interacting sites on RASEF   
To define the ERK1/2-interacting sites on RASEF protein, we constructed 
various vectors expressing partial RASEF protein with Flag-tag at its N-terminus, 
and transfected either of them into RASEF-negative DMS114 cells.  
Immunoprecipitation using anti-Flag M2 agarose and subsequent 
immunoblotting with anti-ERK1/2 antibody were performed as described above. 
 
Synthesized dominant-negative peptide   
To further investigate the biological importance of the interaction between 
RASEF and ERK1/2 that had been confirmed by above mentioned assays in 
lung cancer cell growth, the three different 23-amino-acid polypeptides covering 
the ERK1/2-interacting site on RASEF 520-575 with a membrane-permeable 11 
residues of arginine (11R) at its N-terminus (11R-RASEF 520-542, 
RRRRRRRRRRR-GGG-SALSPQTDLVDDNAKSFSSQKAY; 11R-RASEF 
536-558, RRRRRRRRRRR-GGG-FSSQKAYKIVLAGDAAVGKSSFL; 
11R-RASEF 553-575, 
RRRRRRRRRRR-GGG-GKSSFLMRLCKNEFRENISATLG) were synthesized 
as previously described (17, 20, 28, 29).  Scramble peptides (SCR) derived 
from the 11R-RASEF 553-575 peptides that showed growth suppressive effect 
on cancer cells were synthesized as a control 
(RRRRRRRRRRR-GGG-RSENKMSLFRGSEFTLLKGCINA).  Peptides were 
purified by preparative reverse-phase high-performance liquid chromatography 
with the purity of >95%.  Two RASEF-positive cell lines A549 and NCI-H2170, 
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and RASEF-negative bronchial epithelial cells BEAS-2B were cultured in the 
presence of either of these peptides in media at the concentration of 5, 10, or 15 
μM for 5 days.  The medium was replaced at every 48 hours with the 
above-mentioned concentrations of each peptide, and the viability of cells was 
evaluated by MTT assay. 
 
Results 
RASEF expression in lung cancers and normal tissues   
To identify novel molecules that can be applicable for the development of novel 
biomarkers and treatments on the basis of the biological characteristics of 
cancer cells, we had performed genome-wide gene expression profile analysis 
of 120 lung carcinomas using a cDNA microarray (6–10).  Among 27,648 genes 
or expressed sequence tags screened, we identified elevated expression (5-fold 
or higher) of RASEF transcript in the great majority of the lung cancer samples 
examined.  We confirmed by semi-quantitative RT-PCR experiments RASEF 
expression in 9 of 12 clinical lung cancers, but its expression was hardly 
detectable in their corresponding normal lung tissues (Fig. 1A).  We also 
observed overexpression of RASEF in 14 of 22 lung cancer cell lines, but did not 
detect its expression in BEAS-2B airway epithelial cells (Fig. 1B).  To evaluate 
the expression levels and subcellular localization of RASEF protein in lung 
cancer cells, we performed Western blotting and immunofluorescence analyses 
using a rabbit anti-RASEF polyclonal antibody and RASEF-positive lung cancer 
A549 and NCI-H2170 cells, and RASEF-negative DMS114 cells as well as 
BEAS-2B airway epithelial cells.  The band was detected by Western blotting at 
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the molecular weight of about 90kD in RASEF-positive A549 and NCI-H2170 
cells, whereas no signal was detected in RASEF-negative DMS114 and 
BEAS-2B cells (Fig. 1C).  Since there are several predicted phosphorylation 
sites on RASEF, we treated the lysate of NCI-H2170 cells with phosphatase, 
and observed by immunoblotting the disappearance of the upper weak signals, 
suggesting the phosphorylation of a part of RASEF protein in cancer cells 
(Supplementary Fig. S1).  We also detected by immunofluorescence analysis 
RASEF protein mainly in the cytoplasm of RASEF-positive A549 and NCI-H2170 
cells, but not in RASEF-negative DMS114 and BEAS-2B cells (Fig. 1D). 
Northern blot analysis using a RASEF cDNA fragment as a probe 
identified a 5.8-kb transcript only in prostate and testis, but not in any other 
normal tissues examined (Fig. 2A).  We also examined by 
immunohistochemical analysis expression of RASEF protein in six normal 
human tissues (liver, heart, kidney, lung, prostate, and testis) and lung cancer 
tissues (ADC, SCC, and SCLC).  Strong positive RASEF staining was mainly 
observed in cytoplasm of lung tumor cells, and weakly in prostate and testicular 
cells, but its staining was hardly detectable in the remaining four normal tissues 
(Fig. 2B).  The comparison of RASEF staining in NSCLC and adjacent normal 
tissues from 10 patients who underwent surgery revealed that RASEF protein 
was highly expressed in NSCLC tissues, but not in adjacent normal lung tissues 
(Fig. 2C). 
 
Association of RASEF expression with poor prognosis for NSCLC patients 
To investigate the biological and clinicopathological significance of RASEF in 
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pulmonary carcinogenesis, we carried out immunohistochemical staining on 
tissue microarray containing 341 NSCLC cases that underwent surgical 
resection, using a rabbit polyclonal antibody specific to RASEF.  We classified 
a pattern of RASEF expression on the tissue array ranging from absent (scored 
as 0) to weak/strong positive (scored as 1+ to 2+; representative images of 
staining were shown in Fig. 2D).  Of the 341 NSCLCs, RASEF was strongly 
stained in 126 (37%) cases (score 2+), weakly stained in 150 (44%) cases 
(score 1+), and not stained in 65 (19%) cases (score 0) (Table 1A).  Using the 
scores of RASEF staining, we examined the association between RASEF 
positivity and prognosis of NSCLC patients, and found that the prognosis of 
NSCLC was likely to be poorer in patients with the higher scores of RASEF 
positivity than those with the lower scores, although there is no significant 
difference of survival periods between NSCLC patients with weak 
RASEF-positive tumors and those with RASEF-negative (Supplementary Fig. 
S2).  Therefore we next examined correlation of RASEF expression (strong 
positive vs weak positive/absent) with prognosis of patients as well as various 
clinicopathologic parameters such as age, gender, smoking status (never 
smoker vs current or former smoker), pathologic tumor stage (tumor size; T1 vs 
T2-3), pathologic node stage (node status; N0 vs N1-2), and histology (ADC vs 
other histological types), and found that strong RASEF positivity was associated 
with poor prognosis of patients with NSCLC after the resection of primary tumors 
(P < 0.0001 log-rank test; Fig. 2E).  In addition, we found that high levels of 
RASEF expression were significantly correlated with tumor size (T factor; 
P=0.0006, Table 1A).  Furthermore, we applied univariate analysis to evaluate 
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associations between patient prognosis and several factors including age, 
gender, smoking status, pathologic tumor stage, pathologic node stage, 
histology, and RASEF status (score 0, 1+ vs score 2+).  All those variables 
except smoking status were significantly associated with poor prognosis.  
Multivariate analysis using a Cox proportional hazard model indicated that 
RASEF (P = 0.0034) as well as other three factors (age, tumor size, and lymph 
node metastasis) were independent prognostic factors for surgically treated 
NSCLC patients (Table 1B).  To further confirm the independent prognostic 
value of strong RASEF expression, we performed subgroup analysis of stage I 
NSCLCs by log-rank test, and found that strong RASEF positivity was 
associated with poor prognosis of patients with stage I NSCLC (P = 0.0004).  
We also confirmed prognostic value of RASEF in another independent set of 243 
postoperative NSCLC patients (P = 0.0382 log-rank test; Supplementary Fig. 
S3). 
 
Growth effect of RASEF protein   
To disclose the role of RASEF in the growth or survival of cancer cells, we 
suppressed endogenous RASEF expression using two siRNAs against RASEF 
(si-RASEF-#1 and -#2), along with two control siRNAs (siRNAs for EGFP and 
LUC).  Transfection of si-RASEFs into lung cancer cells decreased the level of 
RASEF protein, and resulted in significant reduction of cell viability and colony 
numbers measured (Figs. 3A-C; statistical analysis of colony formation assay is 
in Supplementary Fig. S4).  These results suggest that RASEF is 
indispensable for cell growth or survival of lung cancer cells. 
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We further evaluated the role of RASEF in cell growth by introducing RASEF 
expression vector or mock plasmid into BEAS-2B bronchial epithelial cells and 
DMS114 lung cancer cells, which scarcely expressed endogenous RASEF.  We 
observed significantly rapid growth of the cells transfected with RASEF 
expression vector compared with those with mock plasmid (Figs. 3D and 3E).  
These data further imply RASEF to be important for growth of cells. 
 
Elevation of phosphorylated ERK1/2 by RASEF expression 
Since it has been reported that some Rab proteins were involved in the positive 
regulation of Mitogen-activated protein kinase (MAPK) cascade that is 
well-known to be crucial for cell proliferation (44, 45), we subsequently examined 
the possibility that RASEF could affect the activity of MAPK cascade in lung 
cancer cells.  We first investigated by Western blot analysis of lung cancer cells 
the phosphorylation levels of three MAPK molecules, c-Raf, MEK1/2, and 
ERK1/2 according to the levels of RASEF introduction or reduction.  
Transfection of RASEF-expression vector into endogenous RASEF-negative 
DMS114 cells increased the levels of phospho-ERK1/2 (pERK1/2) compared 
with that of mock vector, whereas the levels of total ERK1/2 protein were not 
different between the cells transfed with RASEF-expression vector and those 
with mock vector  (Fig. 4A).  In addition, transfection of siRNAs for RASEF 
into endogenous RASEF-positive NCI-H2170 cells suppressed RASEF 
expression, and resulted in significant decrease of the phosphorylated ERK1/2 
(pERK1/2), but not total ERK1/2 (Fig. 4B).  The levels of pMEK1/2 and pc-Raf 
as well as total MEK1/2 and total c-Raf, which are upstream kinases of ERK1/2 
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were not changed in these two assays (Figs. 4A and 4B), suggesting that 
RASEF protein expression could selectively enhance ERK1/2 phosphorylation.  
Moreover, transfection of RASEF-expression vector into RASEF-negative 
DMS114 cells increased the phosphorylation levels of RSK (pRSK (T359/S363)), 
but did not affect the levels of total RSK which is one of the substrate of ERK1/2 
kinase, while inhibition of RASEF protein expression by siRNAs for RASEF in 
RASEF-positive NCI-H2170 cells reduced the levels of pRSK (T359/S363), but 
not those of total RSK, implying that RASEF protein expression could activate 
downstream cascade of ERK1/2 such as RSK (Figs. 4A and 4B). 
We also evaluated by semi-quantitative RT-PCR the expression levels of 
CCND1 CCNB1, and CDKN1A which were known to be transcriptionally up- or 
down-regulated by MAPK pathway (46, 47).  CCND1 and CCNB1 are reported 
to be transactivated by activation of MAPK pathway, while CDKN1A is negatively 
regulated.  As expected, overexpression of RASEF protein in RASEF-negative 
BEAS-2B and DMS114 cells increased the expression of both CCND1 and 
CCNB1, and reduced that of CDKN1A (Fig. 4C).  On the other hand, 
suppression of RASEF protein expression by siRNAs in RASEF-positive A549 
and NCI-H2170 cells reduced the expression of both CCND1 and CCNB1, and 
increased CDKN1A expression (Fig. 4D).  These results indicate that presence 
of RASEF protein might activate ERK1/2 signaling pathway in lung cancer cells.  
Since cell-based assays suggested that the presence of total RASEF protein in 
lung cancer cells could elevate the levels of phospho-ERK1/2, but not those of 
total ERK1/2 protein, we subsequently evaluated the association between total 
RASEF protein expression and the levels of phospho-ERK1/2 in 8 lung cancer 
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cell lines and BEAS-2B cells (Supplementary Fig. S5A).  The Spearman 
correlation coefficient indicated that relative ERK1/2 phosphorylation, which was 
defined as phospho-ERK signal / total ERK protein signal, was significantly 
correlated with expression levels of total RASEF protein (Supplementary Fig. 
S5B), suggesting that presence of total RASEF protein could increase the levels 
of phospho-ERK1/2. 
We further carried out immunohistochemical staining on tissue microarray of 323 
NSCLCs using a rabbit anti-phospho-ERK1/2 (pERK1/2) polyclonal antibody, 
and compared its expression with total RASEF protein positivity, which were 
classified as strong positive, weak positive or absent staining.  We confirmed 
that strong total RASEF protein positivity was significantly correlated with strong 
phospho-ERK1/2 positivity using chi-square test (χ2 = 16.778, P < 0.0001; 
representative images were shown in Supplementary Fig. S6). 
 
Identification of ERK1/2-interacting sites on RASEF  
To investigate the molecular biological mechanism of regulation of ERK1/2 
phosphorylation by total RASEF protein, we examined the interaction between 
endogenous RASEF and ERK1/2 by immunoprecipitation assay using extracts 
from lung cancer NCI-H2170 cells and anti-RASEF antibody, and detected 
binding of endogenous RASEF to endogenous ERK1/2 (Fig. 5A), suggesting 
that phosphorylation of ERK1/2 was likely to be increased through its interaction 
with RASEF.  The results support the hypothesis that total RASEF protein 
expression might play important role in a subset of clinical lung cancers probably 
through its interaction with and subsequent enhancement of the phosphorylation 
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levels of ERK1/2. 
To narrow down the ERK1/2-interacting sites on RASEF, we first constructed 3 
vectors expressing partial RASEF protein with Flag-tag (RASEF1-240, 
RASEF170-520, and RASEF455-740; Fig. 5B) and transfected either of them into 
DMS114 cells.  Immunoprecipitation assay indicated that the only 
COOH-terminal portion of RASEF (RASEF455-740) including a RAB domain was 
able to bind to endogenous ERK1/2 (Fig. 5C).  To further define the minimal 
ERK1/2-interacting sites, we constructed 4 additional vectors expressing 
55-amino-acid protein derived from a COOH-terminal portion of RASEF 
(RASEF520-575, RASEF575-630, RASEF630-685 and RASEF685-740; Fig. 5A) and 
transfected either of them into DMS114 cells.  Immunoprecipitation assay with 
anti-Flag M2 agarose and subsequent Western blotting with anti-ERK1/2 
antibody revealed that RASEF520-575 was able to bind to ERK1/2, but other 
peptides were not (Fig. 5D).  These experiments indicate that the 
55-amino-acid polypeptide in RASEF (codons 520-575) should be responsible 
for the interacting to ERK1/2. 
 
Growth inhibition of lung cancer cells by dominant-negative peptides 
inhibiting RASEF-ERK1/2 interaction   
To examine whether RASEF-ERK1/2 interaction could be essential for cancer 
cell growth, we synthesized three different kinds of 23-amino acid polypeptides 
covering the ERK1/2-interacting site on RASEF at codons 520-575 with 
membrane-permeable 11 residues of arginine (11R) at its N-terminus 
(11R-RASEF520-542, 11R-RASEF536-558, and 11R-RASEF553-575) (Fig. 6A).  
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Initially, we evaluated the effect of inhibition of the RASEF-ERK1/2 interaction on 
lung cancer cell growth, we incubated RASEF-positive A549 and NCI-H2170 
cells, and RASEF-negative BEAS-2B cells with each of the three peptides at the 
final concentration of 5, 10, or 15 μM in culture media.  MTT assay revealed 
that the only 11R-RASEF553-575 peptide showed growth suppressive effect on 
A549 and NCI-H2170 cells on a dose-dependent manner, but not on BEAS-2B 
cells (Figs. 6B and 6C).  We also confirmed by immunoprecipitation assay 
using antibodies to RASEF and ERK1/2 that the endogenous RASEF-ERK1/2 
binding was inhibited by addition of 11R-RASEF553-575 peptides, but not its 
control scramble peptides into culture media of lung cancer NCI-H2170 cells 
(Fig. 6D).  The results suggest that RASEF-ERK1/2 interaction plays a critical 
role in lung cancer cell growth. 
 
Discussion 
Recent accumulation of knowledge in cancer genomics introduced new 
strategies for cancer treatment such as molecular-targeted therapy (5).  
Molecular targeted drugs are expected to be highly specific to malignant cells, 
with minimal adverse effects due to their well-defined mechanisms of action.  
To find such molecules, we established an effective screening system to identify 
proteins that were activated specifically in lung cancer cells.  The strategy was 
as follows: (a) identification of up-regulated genes in 120 lung cancer samples 
through the genome-wide gene expression profiles analysis, covering 27,648 
genes or ESTs, coupled with laser microdissection; (b) verification of very low or 
absent expression of genes in normal organs by cDNA microarray analysis and 
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multiple-tissue Northern blot analysis; (c) confirmation of the clinicopathologic 
significance of their overexpression using tissue microarray consisting of 
hundreds of NSCLC tissue samples; and (d) verification of the targeted genes 
whether they are essential for the survival or growth of lung cancer cells by 
siRNA.  Through this screening system, we have found that RASEF is 
overexpressed commonly in clinical lung cancer samples and cell lines, and its 
gene product plays an important role in the growth of lung cancer cells. 
RASEF is described as a member of Rab GTPase family which generally plays 
important roles in vesicle trafficking.  To date, a few studies indicated aberrant 
expression of RASEF in human cancers, but results were contradictory; RASEF 
was reported to be down-regulated in uveal melanomas, whereas it was 
overexpressed in esophageal squamous cell carcinomas (48, 49).  To examine 
the mechanism of RASEF activation and overexpression in lung cancer, we 
checked previous publications and databases for RASEF including the data of 
CGH and genome sequencing (http://cancer.sanger.ac.uk/cosmic/gene/).  
However, missense mutation was indicated in 10 of 904 (1.1%) lung cancers, but 
no amplification or translocation of RASEF gene was reported in lung cancers.  
Therefore, we speculate that overexpression of RASEF may be mainly caused 
by epigenetic mechanism.  Further analysis of RASEF including screening of 
activating mutation by functional assays and/or mechanism of epigenetic 
regulation of RASEF might further clarify the oncogenic function of RASEF. 
In this study, we confirmed that inhibition of expression of endogenous RASEF 
by siRNA resulted in marked reduction of cell viability of lung cancer cells, and 
that exogenously-introduced RASEF promoted cell growth.  Moreover, tissue 
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microarray analysis using two independent sample sets revealed that strong 
RASEF expression was a prognostic factor for surgically-treated NSCLC 
patients.  Interestingly, several openly available microarray databases also 
independently support our data that the higher expression of RASEF is likely to 
associate with the poorer prognosis of lung cancer patients (PrognoScan; 
http://www.prognoscan.org/).  The data suggest that RASEF contributes to 
viability and malignant potential of lung cancer cells and should be a clinically 
promising prognostic biomarker and novel molecule target for this disease. 
Several Rab proteins have been reported to activate the MAPK cascade that is 
an important intracellular signaling pathway for cell proliferation, cell survival, 
development, cell cycle, angiogenesis, and cell migration.  Rab11 regulates 
JNK pathway as well as typical MAPK cascade during Drosophila wing 
development (44), whereas RBEL1 (Rab-like protein 1) is thought to promote 
cell growth through activation of ERK signaling in breast cancer cells (45).  We 
examined whether presence of total RASEF protein could affect the activity of 
MAPK signal molecules by transfection of siRNAs for RASEF or 
RASEF-expression vectors into lung cancer cells, and found that presence of 
total RASEF protein could elevate the levels of phospho-ERK1/2, but not the 
amount of total ERK1/2 protein in lung cancer cells probably through its 
interaction with total ERK1/2. 
Somatic EGFR mutation was reported to be biologically important for the clinical 
response of NSCLCs to EGFR tyrosine kinase inhibitors such as gefitinib or 
erlotinib (3, 5).  To examine the relevance of strong RASEF expression to this 
type of NSCLCs with EGFR mutation, we examined the association between 
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RASEF overexpression and EGFR mutation status in NSCLC tissues (325 cases 
available) by using specific antibodies to E746-A750 deletion and those to a 
point mutation (L858R) in EGFR, and found that there was no exclusive or 
inclusive relationship between strong RASEF expression and EGFR mutation 
status, although the frequency of EGFR mutation was higher in NSCLCs with 
strong RASEF positive compared to those with RASEF weak positive or 
negative (44% vs 25%, P = 0.0012, Chi-square test).  RASEF may play an 
essential role in various types of lung cancer including those with other driver 
mutations. 
Since inhibition of interaction between RASEF and ERK1/2 by RASEF-derived 
peptides with a membrane-permeable 11 residues of arginine (11R) at its 
N-terminus inhibited the growth of RASEF-positive lung cancer cells, targeting 
RASEF-ERK1/2 interaction as well as RASEF itself by small molecules and/or 
nucleic acid drugs is one of the possible therapeutic approaches for cancer.  
The MAPK cascade is well characterized to play a critical role in human 
carcinogenesis, and has been the subject of intense research for discovery of 
novel anticancer drugs.  Selumetinib (AZD6244, ARRY-142886), a selective 
inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2), was reported 
to be effective for a subset of cancer patients in clinical trials, but adverse 
reactions are also observed in a certain portion of the patients (50).  Therefore, 
targeting therapy against cancer-specific co-activator or mediator of MAPK 
cascade, which is expressed specifically in cancer tissues, but not in normal 
tissues, should be an alternative approach for cancer treatment with less 
adverse events.  Although the function of RASEF in carcinogenesis remains 
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unclear, therapeutic strategy targeting RASEF and/or RASEF-ERK1/2 
interaction is thought to have a great potential. 
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Figure legends 
Figure 1.  RASEF expression in tumor tissues and cell lines. 
A, Expression of RASEF in 12 clinical lung cancers [T; 4 clinical lung 
adenocarcinomas (ADC), 4 clinical lung squamous cell carcinomas (SCC) and 4 
clinical small cell lung cancers (SCLC)] and corresponding normal lung tissues 
(N) detected by semiquantitative RT-PCR analysis.  B, Expression of RASEF in 
22 lung cancer cell lines and a bronchial epithelial cell line BEAS-2B detected by 
semiquantitative RT-PCR analysis.  ASC indicates lung adenosquamous cell 
carcinoma; LCC, large cell carcinoma.  C, Western blot analysis of RASEF 
protein using anti-RASEF antibody.  IB, immunoblotting.  D, Expression and 
subcellular localization of endogenous RASEF protein in RASEF-positive and 
-negative lung cancer cell lines, and bronchial epithelial cells.  RASEF was 
stained mainly at the cytoplasm in A549 and NCI-H2170 cells, whereas no 
staining was observed in DMS114 and bronchial epithelia derived BEAS-2B cell 
lines. 
 
Figure 2.  RASEF expression in tumor tissues and normal tissues. 
A, Northern blot analysis of the RASEF transcript in 16 normal adult human 
tissues.  A weak signal was observed in only prostate and testis.  B, 
Expression of RASEF protein expression between normal tissues and lung 
cancers by immunohistochemistry.  Original magnification, X200. C, 
Immunohistochemistry of lung tumor tissues and adjacent normal lung tissues. 
Original magnification, X100. D, E, Prognostic significance of high RASEF 
expression in surgically treated non-small cell lung cancer (NSCLC) patients 
evaluated by tissue microarray.  Examples for strong, weak, and absent RASEF 
expression in lung cancer tissues and a normal tissue (D).  Original 
magnification, x100.  Kaplan-Meier analysis of tumor-specific survival of 
NSCLC patients (n = 341) who underwent resection of primary tumors according 
to expression levels of RASEF (P < 0.0001 by log-rank test) (E).  Makers on 
survival curves mean censored cases. 
 
Figure 3. Growth promoting effect of RASEF. 
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A-C, Inhibition of growth of lung cancer cells by siRNAs against RASEF. 
Knockdown of RASEF protein expression in A549 and NCI-H2170 cells 
transfected with si-RASEFs (#1 and #2) and control siRNAs (si-EGFP and 
si-LUC), analyzed by Western blotting (A).  Cell viability and colony numbers 
detected by MTT assay (B) and Colony formation assay (C).  D, E, Growth 
promotion of BEAS-2B and DMS114 cells by overexpression of exogenous 
RASEF.  Detection of transient RASEF expression by Western blot analysis 
with anti-Flag antibody (D).  MTT assays of BEAS-2B and DMS114 cells 120 
hours after transfection of RASEF-expressing vector (E).  Columns, relative 
absorbance of triplicate assays; bars, SD. 
 
Figure 4. Enhanced phosphorylation of ERK1/2 by RASEF in lung cancer cells. 
A, Expression of MAPK signal molecules and their phosphorylation levels in 
DMS114 cells transfected with RASEF-expression vector or mock plasmid.  B, 
Expression of MAPK signal molecules and their phosphorylation levels in 
NCI-H2170 cells transfected with siRNAs for RASEF (si-RASEF#2) or control 
siRNAs (si-LUC).  C, D, Expression levels of downstream target genes of 
MAPK cascade were regulated by RASEF expression in lung cancer cells.  
Total RNA from BEAS-2B and DMS114 cells transfected with RASEF-expression 
vector or mock plasmid (C) and A549 and NCI-H2170 cells transfected with 
siRNAs for RASEF (si-RASEF#2) or control siRNAs (si-LUC) (D) were subjected 
to reverse-transcription reaction, followed by PCR reaction to evaluate the 
expression levels of CCND1, CCNB1, and CDKN1A transcription.  Western 
blotting with anti-phosphorylated ERK1/2 antibody was performed to confirm the 
change of ERK1/2 phosphorylation according to RASEF expression.   
 
Figure 5.  Identification of ERK1/2-interacting sites on RASEF. 
A, Interaction of endogenous RASEF with endogenous ERK1/2.  The 
immunoprecipitates obtained using anti-RASEF antibody were subjected to 
Western blotting with anti-ERK1/2 antibody.  B, Schematic representation of 
various partial constructs of RASEF expression vector.  C, D, Determination of 
the ERK1/2-interacting regions on RASEF by immunoprecipitation experiments 
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using DMS114 cells transfected with vectors expressing partial RASEF protein.  
COOH-terminal part of RASEF (codons 520-575) was likely to be 
ERK1/2-interacting region. 
 
Figure 6. Growth inhibition of lung cancer cells by dominant-negative peptides 
inhibiting RASEF-ERK1/2 interaction. 
A, Schematic drawing of three cell-permeable peptides of RASEF covering 
codons 520-575 of RASEF that corresponds to the ERK-interacting region.  B, 
C, Growth suppressive effect of dominant-negative peptides on lung cancer cells.  
11R-RASEF553-575 peptides showed dose-dependent growth suppressive effect 
on RASEF-positive cells.  Columns, relative absorbance of triplicate MTT 
assays; bars, SD; *, P < 0.05; **, P < 0.0001; N.S., Not significant.  D, Inhibition 
of binding between endogenous RASEF and ERK1/2 using cell-permeable 
peptide, detected by immunoprecipitation assay.  NCI-H2170 cells were lysed 
after treatment either with 11R-RASEF553-575 peptides or with scramble peptide 
for 4 hours.  The immunoprecipitates with anti-RASEF antibody were subjected 
to Western blotting with anti-ERK1/2 antibody. 
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Table 1A. Association between RASEF-positivity in NSCLC tissues and patients' characteristics 
(n=341) 
     RASEF expression P value 
   Total 
Strong  
expression 
Weak 
expression 
Absent 
expression strong vs  
weak or absent
   n=341 n=126 n=150 n=65 
Gender        
 Female 100 33 47 20 0.3885 
 Male 241 93 103 45   
Age(year)        
 < 65 160 59 70 31 0.9999 
 >=65 181 67 80 34   
Smoking status        
 never smoker 93 33 39 21 0.8014 
 current or ex-smoker 248 93 111 44   
Histological type        
 ADC 205 68 96 41 0.1094 
 non-ADC 136 58 54 24   
T factor        
 T1 141 37 68 36 0.0006* 
 T2+T3 200 89 82 29   
N factor        
 N0 223 74 100 49 0.0590  
 N1+N2 118 52 50 16   
*P < 0.05 (Fisher's exact test) 
ADC, adenocarcinoma 
non-ADC, squamouse cell carcinoma plus large cell carcinoma and adenosquamous cell carcinoma 
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Table 1B.  Cox’s proportional hazards model analysis of prognostic factors in patients with 
NSCLCs  
Variables Hazards ratio 95% CI Unfavorable/Favorable  P-value 
Univariate analysis         
 RASEF 2.065 1.458-2.927 strong positive /  weak positive or absent <0.0001* 
 Age ( years ) 1.488 1.042-2.125  >= 65 / 65 > 0.0287* 
 Gender 1.612 1.065-2.441 Male / Female 0.0239* 
 Smoking status 1.288 0.855-1.941 Current or ex-smoker / never smoker 0.2252 
 Histological type 1.427 1.007-2.023 non-ADC/ADC 0.0455* 
 pT factor 2.824 1.874-4.255 T2+T3 / T1 <0.0001* 
 pN factor 2.538 1.791-3.596 N1+N2 / N0 <0.0001* 
Multivariate analysis         
 RASEF 1.697 1.191-2.418 strong positive /  weak positive or absent 0.0034* 
 Age ( years ) 1.663 1.158-2.389  >= 65 / 65 > 0.0058* 
 Gender 1.299 0.822-2.054 Male / Female 0.2620 
 Histological type 0.902 0.612-1.330 non-ADC/ADC 0.6033 
 pT factor 2.171 1.403-3.361 T2+T3 / T1 0.0005* 
 pN factor 2.200 1.532-3.158 N1+N2 / N0 <0.0001* 
ADC, adenocarcinoma 
non-ADC, squamous-cell carcinoma plus large-cell carcinoma and adenosquamous-cell carcinoma 
*P < 0.05 
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